Skip to main content

Table 2 Quality assessment of the included studies

From: Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis

Study

I

II

III

IV

V

VI

VII

VIII

Total

Shuguang Ju (2021) [20]

2

2

2

2

2

2

2

1

15

Guosheng Yuan (2021) [25]

2

2

1

2

2

1

2

1

13

Jianming Xu (2021) [21]

2

2

2

2

1

2

2

1

14

Zhiming Zeng (2021) [23]

2

2

1

2

1

1

2

2

13

Yongxiang Xia (2022) [24]

2

2

1

2

2

1

1

1

12

Kuimin Mei (2021) [22]

2

2

1

2

1

2

1

2

13

Jianming Xu (2019) [19]

2

2

1

2

1

2

1

2

13

Guosheng Yuan (2020) [26]

2

2

2

2

1

2

1

2

14

Shukui Qin (2023) [27]

2

2

1

2

2

2

2

2

15

Dongbo Chen (2023) [28]

2

2

1

2

2

1

2

2

14

  1. MINORS index for included non-randomized studies
  2. Numbers I-VIII in heading signified:I, a clearly stated aim;II, inclusion of consecutive patients;III, prospective collection of data; IV, endpoints appropriate to the aim of the study; V, unbiased assessment of the study endpoint;VI, follow-up period appropriate to the aim of the study;VII, loss of follow up less than 5%;VIII, prospective calculation of the study size
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us